GLP-1 weight-loss drugs are now the center of a federal crackdown. The FDA has begun seizing counterfeit semaglutide and tirzepatide products from the U.S. supply chain. Some vials contained bacterial contamination. Others were mislabeled or chemically altered. The agency confirmed more than 500 adverse event reports tied to compounded versions. Poison control centers logged nearly 3,000 semaglutide-related calls in 2023. Most involved off-brand or unregulated formulations.
The crackdown follows a surge in demand. GLP-1s like Ozempic, Wegovy, Zepbound and Mounjaro are now prescribed to more than 15 million Americans. But insurance coverage remains fractured. In 2025, Blue Cross and BCN dropped all GLP-1 weight-loss coverage for fully insured large group plans. CVS Caremark removed Zepbound from its formulary. That left patients scrambling. Many turned to compounding pharmacies, where monthly costs dropped from $1,200 to $200. But the FDA says those versions are no longer legal. Shortages have ended. Emergency compounding is no longer justified.
The impact on pharmacies is brutal. Olympia Pharmaceuticals was producing compounded GLP-1s for 70,000 patients per week. That business is now shuttered. Outsourcing facilities face audits. State boards are issuing cease-and-desist letters. Some pharmacies are trying to skirt the ban by adding B12 or altering dosage formats. The FDA says that won’t fly. Enforcement begins May 22.
Lawmakers are stepping in. Thirty-eight attorneys general signed a letter demanding federal action. Tennessee AG Skrmetti warned that foreign sellers are repackaging insulin and marketing it as Ozempic. Some counterfeit products contain undisclosed ingredients. Others are labeled “for research use only” but sold with dosing instructions. Senator Marsha Blackburn called the trend “a growing threat to public health.” Colorado AG Phil Weiser said the FDA must act before another compounding disaster hits. He cited the 2012 meningitis outbreak that killed 60.
The pharmacy collapse is broader than GLP-1s. Independent shops are closing. Chain stores like Rite Aid and Walgreens are slashing hours and laying off staff. CVS is outsourcing fulfillment to robotics. Patients are left with fewer options and higher costs. The compounding ban is accelerating that collapse. The FDA says safety comes first. Patients say access is gone.
https://thehill.com/opinion/healthcare/5420720-fda-crackdown-compounded-drugs/
https://coag.gov/press-releases/weiser-fda-counterfeit-weight-loss-drugs-2-21-25/